Treprostinil Inhalation Powder ( DrugBank: Treprostinil )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,181 /  Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03950739 (ClinicalTrials.gov)	September 17, 2019	9/5/2019	Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso	An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso	Pulmonary Arterial Hypertension	Drug: Treprostinil Inhalation Powder	United Therapeutics	NULL	Active, not recruiting	18 Years	N/A	All	51	Phase 1	United States
2	NCT03464864 (ClinicalTrials.gov)	March 9, 2018	1/3/2018	Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers	A Phase 1, Single-center, Open-label, Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder (TrIP) in Healthy Normal Volunteers	Pulmonary Arterial Hypertension	Drug: Treprostinil Inhalation Powder	Mannkind Corporation	NULL	Completed	18 Years	55 Years	All	36	Phase 1	United States